Inbiomotion, a Barcelona based company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage breast cancer patients, recently presented analyses of Phase 3 data from landmark trials.
Dr Kathleen Rickard, MD, Chief Medical Officer of Verona Pharma, highlights the debilitating impacts of Chronic Obstructive Pulmonary Disease (COPD) and the need for novel therapeutic approaches to help relieve the burden on patients and caregivers.
In Vivo ‘Rising Leader’ Thijs Cohen Tervaert, Junior Partner at INKEF shared his thoughts with In Vivo’s Jo Shorthouse on the European funding landscape, the importance of software, and sustainable investments, and his investment priorities.
HealthTech For Care’s HealthTech Innovation Days (HTID#4) returns on 12-14 October in Paris and virtually. This year, Optimum is a proud supporter of HTID#4 investor relations.
Optimum Strategic Communications is delighted to announce that ISA Pharmaceutical’s Chief Scientific Officer and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of Immuno-Oncology (FAIO).
